Insulin-Like Actions of Vanadium: Potential as a Therapeutic Agent

Journal of Trace Elements in Experimental Medicine

Volumn 16, Issue 4, 2003, Pages 253-267

  Marzban, Lucy ^a   McNeill, John H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; VANADIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONCENTRATION RESPONSE; CONFERENCE PAPER; DRUG MECHANISM; ENZYME INHIBITION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HORMONAL REGULATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN LIKE ACTIVITY; INSULIN SENSITIVITY; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

EID: 0242490984     PISSN: 0896548X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jtra.10034     Document Type: Conference Paper

References (84)

1. Brichard SM, Henquin JC. The role of vanadium in the management of diabetes. Trends Pharmacol Sci 1995;16:265-270.
2. Thompson KH, McNeill JH, Orvig C. Vanadium compounds as insulin mimics. Chem Rev 1999;99:2561-2571.
3. De Cremer K, Van Hulle M, Chery C, Cornelis R, Strijckmans K, Dams R, Lameire N, Vanholder R. Fractionation of vanadium complexes in serum, packed cells and tissues of Wistar rats by means of gel filtration and anion-exchange chromatography. J Biol Inorg Chem 2002;7:884-890.
4. Shechter Y, Karlish SJ. Insulin-like stimulation of glucose oxidation in rat adipocytes by vanadyl [IV] ions. Nature 1980;284:556-558.
5. Cam MC, Brownsey RW, McNeill JH. Mechanisms of vanadium action: insulin-mimetic or insulin-enhancing agent? Can J Physiol Pharmacol 2000;78:829-847.
6. Goldwaser I, Gefel D, Gershonov E, Fridkin M, Shechter Y. Insulin-like effects of vanadium: basic and clinical implications. J Inorg Biochem 2000;80:21-25.
7. Domingo JL, Gomez M, Llobet JM, Corbella J, Keen CL. Oral vanadium administration to streptozotocin-diabetic rats has marked negative side-effects which are independent of the form of vanadium used. Toxicology 1991;66:279-287.
8. Dai S, Thompson KH, Vera E, McNeill JH. Toxicity studies on one-year treatment of non-diabetic and streptozotocin-diabetic rats with vanadyl sulphate. Pharmacol Toxicol 1994;75:265-273.
9. Srivastava AK. Anti-diabetic and toxic effects of vanadium compounds. Mol Cell Biochem 2000;206:177-182.
10. McNeill JH, Yuen VG, Dai S, Orvig C. Increased potency of vanadium using organic ligands. Mol Cell Biochem 1995;153:175-180.
11. Poucheret P, Verma S, Grynpas MD, McNeill JH. Vanadium and diabetes. Mol Cell Biochem 1998;188:73-80.
12. Sekar N, Li J, Shechter Y. Vanadium salts as insulin substitutes: mechanisms of action, a scientific and therapeutic tool in diabetes mellitus research. Crit Rev Biochem Mol Biol 1996;31:339-359.
13. Lyonnet BMM, Martin E. L'emploi therapeutique des derives du vanadium. La Presse Medicale 1899;32:191-192.
14. Heyliger CE, Tahiliani AG, McNeill JH. Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. Science 1985;227:1474-1477.
15. Blondel O, Bailbe D, Portha B. In vivo insulin resistance in streptozotocin-diabetic rats-evidence for reversal following oral vanadate treatment. Diabetologia 1989;32:185-190.
16. Ramanadham S, Mongold JJ, Brownsey RW, Cros GH, McNeill JH. Oral vanadyl sulfate in treatment of diabetes mellitus in rats. Am J Physiol 1989;257:H904-911.
17. Brichard SM, Pottier AM, Henquin JC. Long term improvement of glucose homeostasis by vanadate in obese hyperinsulinemic fa/fa rats. Endocrinology 1989;125:2510-2516.
18. Bhanot S, McNeill JH. Vanadyl sulfate lowers plasma insulin and blood pressure in spontaneously hypertensive rats. Hypertension 1994;24:625-632.
19. Cohen N, Halberstam M, Shlimovich P, Chang CJ, Shamoon H, Rossetti L. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1995;95:2501-2509.
20. Brichard SM, Desbuquois B, Girard J. Vanadate treatment of diabetic rats reverses the impaired expression of genes involved in hepatic glucose metabolism: effects on glycolytic and gluconeogenic enzymes, and on glucose transporter GLUT2. Mol Cell Endocrinol 1993;91:91-97.
21. Wang Y, Yu B. Effect of peroxovanadate compound on phosphoenolpyruvate carboxykinase gene expression and lipid metabolism in diabetic rats. Drugs Exp Clin Res 1997;23:111-115.
22. Marzban L, Rahimian R, Brownsey RW, McNeill JH. Mechanisms by which bis(maltolato)oxovanadium(IV) normalizes phosphoenolpyruvate carboxykinase and glucose-6-phosphatase expression in streptozotocin-diabetic rats in vivo. Endocrinology 2002;143:4636-4645.
23. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2000;23:S4-19.
24. Notkins AL. Immunologic and genetic factors in type 1 diabetes. J Biol Chem 2002;277:43545-43548.
25. Brichard SM, Okitolonda W, Henquin JC. Long term improvement of glucose homeostasis by vanadate treatment in diabetic rats. Endocrinology 1988;123:2048-2053.
26. Strout HV, Vicario PP, Biswas C, Saperstein R, Brady EJ, Pilch PF, Berger J. Vanadate treatment of streptozotocin diabetic rats restores expression of the insulin-responsive glucose transporter in skeletal muscle. Endocrinology 1990;126:2728-2732.
27. Cam MC, Pederson RA, Brownsey RW, McNeill JH. Long-term effectiveness of oral vanadyl sulphate in streptozotocin-diabetic rats. Diabetologia 1993;36:218-224.
28. Venkatesan N, Avidan A, Davidson MB. Antidiabetic action of vanadyl in rats independent of in vivo insulin-receptor kinase activity. Diabetes 1991;40:492-498.
29. Matsuda M, Mandarino L, DeFronzo RA. Synergistic interaction of magnesium and vanadate on glucose metabolism in diabetic rats. Metabolism 1999;48:725-731.
30. Kopp SJ, Daar J, Paulson DJ, Romano FD, Laddaga R. Effects of oral vanadyl treatment on diabetes-induced alterations in the heart GLUT-4 transporter. J Mol Cell Cardiol 1997;29:2355-2362.
31. Mohammad A, Sharma V, McNeill JH. Vanadium increases GLUT4 in diabetic rat skeletal muscle. Mol Cell Biochem 2002;233:139-143.
32. Li SH, McNeill JH. In vivo effects of vanadium on GLUT4 translocation in cardiac tissue of STZ-diabetic rats. Mol Cell Biochem 2001;217:121-129.
33. Goldfine AB, Simonson DC, Folli F, Patti ME, Kahn CR. Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies. J Clin Endocrinol Metab 1995;80:3311-3320.
34. Battell ML, Yuen VG, McNeill JH. Treatment of BB rats with vanadyl sulphate. Pharmacol Commun 1992;1:291-301.
35. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003;46:3-19.
36. Meyerovitch J, Rothenberg P, Shechter Y, Bonner-Weir S, Kahn CR. Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus. J Clin Invest 1991;87:1286-1294.
37. Pugazhenthi S, Angel JF, Khandelwal RL. Long-term effects of vanadate treatment on glycogen metabolizing and lipogenic enzymes of liver in genetically diabetic (db/db) mice. Metabolism 1991;40:941-946.
38. Brichard SM, Assimacopoulos-Jeannet F, Jeanrenaud B, Vanadate treatment markedly increases glucose utilization in muscle of insulin-resistant fa/fa rats without modifying glucose transporter expression. Endocrinology 1992;131:311-317.
39. Bhanot S, Michoulas A, McNeill JH. Antihypertensive effects of vanadium compounds in hyperinsulinemic, hypertensive rats. Mol Cell Biochem 1995;153:205-209.
40. Yuen VG, Vera E, Battell ML, Li WM, McNeill JH. Acute and chronic oral administration of bis(maltolato)oxovanadium(IV) in Zucker diabetic fatty (ZDF) rats. Diabetes Res Clin Pract 1999;43:9-19.
41. Brichard SM, Ongemba LN, Henquin JC. Oral vanadate decreases muscle insulin resistance in obese fa/fa rats. Diabetologia 1992;35:522-527.
42. Goldfine AB, Patti ME, Zuberi L, Goldstein BJ, LeBlanc R, Landaker EJ, Jiang ZY, Willsky GR, Kahn CR. Metabolic effects of vanadyl sulfate in humans with non-insulin- dependent diabetes mellitus: in vivo and in vitro studies. Metabolism 2000;49:400-410.
43. Pugazhenthi S, Angel JF, Khandelwal RL. Effects of high sucrose diet on insulin-like effects of vanadate in diabetic rats. Mol Cell Biochem 1993;122:77-84.
44. Khandelwal RL, Pugazhenthi S. In vivo effects of vanadate on hepatic glycogen metabolizing and lipogenic enzymes in insulin-dependent and insulin-resistant diabetic animals. Mol Cell Biochem 1995;153:87-94.
45. Yuen VG, Pederson RA, Dai S, Orvig C, McNeill JH. Effects of low and high dose administration of bis(maltolato)oxovanadium(IV) on fa/fa Zucker rats. Can J Physiol Pharmacol 1996;74:1001-1009.
46. Wang J, Yuen VG, McNeill JH. Effect of vanadium on insulin sensitivity and appetite. Metabolism 2001;50:667-673.
47. Wang J, Yuen VG, McNeill JH. Effect of vanadium on insulin and leptin in Zucker diabetic fatty rats. Mol Cell Biochem 2001;218:93-96.
48. Halberstam M, Cohen N, Shlimovich P, Rossetti L, Shamoon H. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes 1996;45:659-666.
49. Cusi K, Cukier S, DeFronzo RA, Torres M, Puchulu FM, Redondo JC. Vanadyl sulfate improves hepatic and muscle insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab 2001;86:1410-1417.
50. Boden G, Chen X, Ruiz J, van Rossum GD, Turco S. Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Metabolism 1996;45:1130-1135.
51. Jentjens RL, Jeukendrup AE. Effect of acute and short-term administration of vanadyl sulphate on insulin sensitivity in healthy active humans. Int J Sport Nutr Exerc Metab 2002;12:470-479.
52. Marzban L, Bhanot S, McNeill JH. In vivo effects of insulin and bis(maltolato)oxovanadium(IV) on PKB activity in the skeletal muscle and liver of diabetic rats. Mol Cell Biochem 2001;223:147-157.
53. Clark AS, Fagan JM, Mitch WE. Selectivity of the insulin-like actions of vanadate on glucose and protein metabolism in skeletal muscle. Biochem J 1985;232:273-276.
54. Fantus IG, Tsiani E. Multifunctional actions of vanadium compounds on insulin signaling pathways: evidence for preferential enhancement of metabolic versus mitogenic effects. Mol Cell Biochem 1998;182:109-119.
55. Hei YJ. Recent progress in insulin signal transduction. J Pharmacol Toxicol Methods 1998;40:123-135.
56. Green A. The insulin-like effect of sodium vanadate on adipocyte glucose transport is mediated at a post-insulin-receptor level. Biochem J 1986;238:663-669.
57. Jackson TK, Salhanick AI, Sparks JD, Sparks CE, Bolognino M, Amatruda JM. Insulin-mimetic effects of vanadate in primary cultures of rat hepatocytes. Diabetes 1988;37:1234-1240.
58. Goldfine AB, Simonson DC, Folli F, Patti ME, Kahn CR. In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus. Mol Cell Biochem 1995;153:217-231.
59. Mohammad A, Wang J, McNeill JH. Bis(maltolato)oxovanadium(IV) inhibits the activity of PTP1B in Zucker rat skeletal muscle in vivo. Mol Cell Biochem 2002;229:125-128.
60. Strout HV, Vicario PP, Saperstein R, Slater EE. The insulin-mimetic effect of vanadate is not correlated with insulin receptor tyrosine kinase activity nor phosphorylation in mouse diaphragm in vivo. Endocrinology 1989;124:1918-1924.
61. Shisheva A, Shechter Y. A cytosolic protein tyrosine kinase in rat adipocytes. FEBS Lett 1992;300:93-96.
62. Pandey SK, Anand-Srivastava MB, Srivastava AK. Vanadyl sulfate-stimulated glycogen synthesis is associated with activation of phosphatidylinositol 3-kinase and is independent of insulin receptor tyrosine phosphorylation. Biochemistry 1998;37:7006-7014.
63. Shisheva A, Shechter Y. Role of cytosolic tyrosine kinase in mediating insulin-like actions of vanadate in rat adipocytes. J Biol Chem 1993;268:6463-6469.
64. Elberg G, He Z, Li J, Sekar N, Shechter Y. Vanadate activates membranous nonreceptor protein tyrosine kinase in rat adipocytes. Diabetes 1997;46:1684-1690.
65. Shepherd PR, Withers DJ, Siddle K. Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochem J 1998;333:471-490.
66. Smith U, Carvalho E, Mosialou E, Beguinot F, Formisano P, Rondinone C. PKB inhibition prevents the stimulatory effect of insulin on glucose transport and protein translocation but not the antilipolytic effect in rat adipocytes. Biochem Biophys Res Commun 2000;268:315-320.
67. Wijkander J, Holst LS, Rahn T, Resjo S, Castan I, Manganiello V, Belfrage P, Degerman E. Regulation of protein kinase B in rat adipocytes by insulin, vanadate, and peroxovanadate. Membrane translocation in response to peroxovanadate. J Biol Chem 1997;272:21520-21526.
68. Mohammad A, Bhanot S, McNeill JH. In vivo effects of vanadium in diabetic rats are independent of changes in PI-3 kinase activity in skeletal muscle. Mol Cell Biochem 2001;223:103-108.
69. Lawrence JC, Jr, Roach PJ. New insights into the role and mechanism of glycogen synthase activation by insulin. Diabetes 1997;46:541-547.
70. Cross DA, Watt PW, Shaw M, van der Kaay J, Downes CP, Holder JC, Cohen P. Insulin activates protein kinase B, inhibits glycogen synthase kinase-3 and activates glycogen synthase by rapamycin-insensitive pathways in skeletal muscle and adipose tissue. FEBS Lett 1997;406:211-215.
71. Semiz S, McNeill JH. Oral treatment with vanadium of Zucker fatty rats activates muscle glycogen synthesis and insulin-stimulated protein phosphatase-1 activity. Mol Cell Biochem 2002;236:123-131.
72. Semiz S, Orvig C, McNeill JH. Effects of diabetes, vanadium, and insulin on glycogen synthase activation in Wistar rats. Mol Cell Biochem 2002;231:23-35.
73. Molero JC, Martinez C, Andres A, Satrustegui J, Carrascosa JM. Vanadate fully stimulates insulin receptor substrate-1 associated phosphatidyl inositol 3-kinase activity in adipocytes from young and old rats. FEBS Lett 1998;425:298-304.
74. Tsiani E, Bogdanovic E, Sorisky A, Nagy L, Fantus IG. Tyrosine phosphatase inhibitors, vanadate and pervanadate, stimulate glucose transport and GLUT translocation in muscle cells by a mechanism independent of phosphatidylinositol 3-kinase and protein kinase C. Diabetes 1998;47:1676-1686.
75. DeFronzo RA. 1988 Lilly lecture. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988;37:667-687.
76. Foster JD, Pederson BA, Nordlie RC. Glucose-6-phosphatase structure, regulation, and function: an update. Proc Soc Exp Biol Med 1997;215:314-332.
77. Hanson RW, Reshef L. Regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression. Annu Rev Biochem 1997;66:581-611.
78. Westergaard N, Brand CL, Lewinsky RH, Andersen HS, Carr RD, Burchell A, Lundgren K. Peroxyvanadium compounds inhibit glucose-6-phosphatase activity and glucagon-stimulated hepatic glucose output in the rat in vivo. Arch Biochem Biophys 1999;366:55-60.
79. Mosseri R, Waner T, Shefi M, Shafrir E, Meyerovitch J. Gluconeogenesis in non-obese diabetic (NOD) mice: in vivo effects of vanadate treatment on hepatic glucose-6-phoshatase and phosphoenolpyruvate carboxykinase. Metabolism 2000;49:321-325.
80. Massillon D. Regulation of the glucose-6-phosphatase gene by glucose occurs by transcriptional and post-transcriptional mechanisms. Differential effect of glucose and xylitol. J Biol Chem 2000;276:4055-4061.
81. Bosch F, Hatzoglou M, Park EA, Hanson RW. Vanadate inhibits expression of the gene for phosphoenolpyruvate carboxykinase (GTP) in rat hepatoma cells. J Biol Chem 1990;265:13677-13682.
82. Anand-Srivastava MB, McNeill JH, Yang XP. Reversal of defective G-proteins and adenylyl cyclase/cAMP signal transduction in diabetic rats by vanadyl sulphate therapy. Mol Cell Biochem 1995;153:113-119.
83. Souness JE, Thompson WJ, Strada SJ. Adipocyte cyclic nucleotide phosphodiesterase activation by vanadate. J Cyclic Nucleotide Protein Phosphor Res 1985;10:383-396.
84. Brownsey RW, Dong GW. Evidence for selective effects of vanadium on adipose cell metabolism involving actions on cAMP-dependent protein kinase. Mol Cell Biochem 1995;153:131-137.